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URGENT CAPSULE ENDOSCOPY IS USEFUL IN SEVERE OBSCURE-OVERT
GASTROINTESTINAL BLEEDING
Nuno Almeida, Pedro Figueiredo, Sandra Lopes, Paulo Freire, Clotilde Lérias, Hermano Gouveia
and Maximino C. Leitão
Department of Gastroenterology, Coimbra University Hospital, Coimbra, Portugal
Aim: With capsule endoscopy (CE) it is possible to examine the entire small bowel. The present study assessed the
diagnostic yield of CE in severe obscure-overt gastrointestinal bleeding (OOGIB).
Methods: During a 3-year period, 15 capsule examinations (4.5% of all CE in a single institution) were carried out in 15
patients (11 men; mean age 69.9 20.1 years) with severe ongoing bleeding, defined as persistent melena and/or hema-
tochezia, with hemodynamic instability and the need for significant red blood cell transfusion. CE was carried out after
non-diagnostic standard upper and lower endoscopy. The mean time from admission until CE was 4.1 4.4 days
(0–15 days).
Results: CE revealed active bleeding in seven patients and signs of recent bleeding in four. Etiology of bleeding was
correctly diagnosed in 11 patients (73.3%) (portal hypertension enteropathy, three patients; subepithelial ulcerated lesion,
two patients; angiodysplasia, two patients; jejunal ulcer with visible vessel, one patient; multiple small bowel ulcers, one
patient; jejunal tumor, one patient; jejunal mucosa irregularity with adherent clot, one patient). One patient (6.7%) had
active bleeding but no visible lesion. As a consequence of the capsule findings, specific therapeutic measures were under-
taken in 11 patients (73.3%) with five managed conservatively, four endoscopically and two surgically. Two patients
experienced bleeding recurrence. One of them, with a probable small bowel tumor, refused any other interventions.
Conclusions: CE is useful in patients with severe OOGIB by providing positive findings in the majority of patients, with
subsequent impact on therapeutic procedures.
Key words: capsule endoscopy, mid-gastrointestinal bleeding, severe overt-obscure gastrointestinal bleeding.
INTRODUCTION
Obscure gastrointestinal bleeding (OGIB) is blood loss
from an unknown source that persists or recurs after a
negative initial endoscopic (colonoscopy, upper endoscopy)
and radiological evaluation.1 Obscure bleeding may be
obscure-occult (i.e. not visible) or obscure-overt (OOGIB)
(i.e. continued passage of visible blood).1 These patients
represent 2–10% of all patients with digestive bleeding, and
they frequently undergo multiple diagnostic procedures and
blood transfusions with increased consumption of health-
care resources.2,3
OGIB is considered severe when any of the following
criteria are present: overt presentation, recurrent episodes
of acute bleeding, transfusion dependence and the need for
hospitalization.4 Severe OGIB represents 1% of all overt
digestive bleedings.4
Intraoperative enteroscopy with a diagnostic yield of
70–100% in OGIB and considered for many years the gold
standard for endoscopic small bowel imaging must be
compared with new methods.5 In fact, capsule endoscopy
(CE) allows the examination of the entire small bowel with
similar diagnostic yield and double balloon enteroscopy
(DBE) permits real-time exploration of the small bowel with
full diagnostic and therapeutic capabilities.5–7 The advent of
these two methods is linked to the emergence of a new defi-
nition in gastroenterology: mid-gastrointestinal bleeding.8
OGIB is the main indication for CE, considered the most
efficient strategy regarding diagnosis, positively predicting
the intestinal diagnosis or normal status in 95.5% of cases.3,9
However, the use of CE after initial negative upper endos-
copy and colonoscopy without a second standard endoscopic
evaluation is controversial because some studies report that a
number of lesions detected by CE are within the reach of
standard endoscopy.10–15
CE has a high positive (95%) and negative predictive
values (83–100%), but the diagnostic yield is influenced by
the timing of the examination and the nature of the bleed-
ing.5,9,16 In fact, patients with ongoing OOGIB are the ones
that benefit the most from CE when compared with patients
with obscure-occult bleeding.5,16–18 Even if no lesion is found,
CE has the potential to, at least, determine the location of the
bleeding.18
In the present study, we aimed to determine the diagnostic
yield, therapeutic changes and final outcome of CE per-
formed shortly after standard endoscopic evaluation in
patients with severe OOGIB.
Correspondence: Nuno Almeida, Gastroenterology Department,
Coimbra’s University Hospital, Avenida Bissaya Barreto and Praceta
Mota Pinto, 3000-075 Coimbra, Portugal. Email: nunoperesalmeida@
gmail.com
Received 21 August 2008; accepted 10 November 2008.
Digestive Endoscopy (2009) 21, 87–92 doi:10.1111/j.1443-1661.2009.00838.x
© 2009 The Authors
© 2009 Japan Gastroenterological Endoscopy Society
METHODS
A total of 330 examinations with CE performed with PillCam
SB (Given Imaging,Yoqneam, Israel) between January 2005
and December 2007 at a single institution were retrospec-
tively evaluated.We considered eligible for study all patients
with severe ongoing bleeding, defined as persistent melena
and/or hematochezia, with periods of hemodynamic instabil-
ity and the need for red blood cell (RBC) transfusion, sub-
mitted for CE after non-diagnostic standard upper and lower
endoscopy.Only urgent CE, defined as non-scheduled exami-
nations carried out in patients with clinical and analytical
signs of ongoing bleeding, immediately after negative stan-
dard upper and lower endoscopies were included.
All but one patient were submitted for colonoscopy in
the previous 24 h, and were fasting for more than 12 h. The
patient that did not undergo colonoscopy had multiple pre-
vious episodes of OGIB with extensive previous work-up,
including colonoscopy and elective CE.As no diagnosis was
previously established, we decided to carry out a CE soon
after the start of a new bleeding episode.
Metoclopramide (10 mg, i.v.) was given to all patients.
After 8 h, the sensor array and the recording device were
removed and the digital video image streams of the exami-
nations were downloaded to the RAPID system (Given
Imaging). The CE digital image stream was assessed and
interpreted by four gastroenterologists with experience in
CE.
Age, sex, time of hospitalization, previous episodes of GI
bleeding and recent medications, results of previous diagnos-
tic work-up tests, including upper endoscopy, colonoscopy,
previous CE, contrast radiography, tagged red blood cell scin-
tigraphy and angiography, were registered. Complications of
the procedure, limitations, rate of total enteroscopy and spe-
cific therapeutic interventions resulting from the CE findings
were also registered. Rebleeding rate was assessed by ana-
lyzing medical records or contacting the referring physicians.
The findings were classified according to a system already
adopted in other studies:9,19 P0 lesions, such as visible sub-
mucosal veins, diverticula without the presence of blood
and nodules without mucosal break, considered to have no
bleeding potential; P1 lesions, such as mucosal red spots or
small/isolated erosions, having uncertain or intermediate
hemorrhagic potential; and P2 lesions, such as typical angio-
mas or angiodysplasias, varices, tumors, large ulcerations and
multiple erosions, considered to have large bleeding poten-
tial. Active bleeding, even without identification of the
hemorrhagic source,was also considered a positive important
finding. Portal hypertension enteropathy, described as areas
of mucosa with a reticulate pattern, was considered a P1
lesion, as its clinical significance regarding digestive bleeding,
is uncertain.20
Descriptive statistics were used to describe the patient’s
demographic features, clinical characteristics, endoscopic
findings and therapeutic procedures. Categorical variables
were presented as percentages and numerical variables as
means and ranges.
All ethical and legal considerations were strictly respected.
RESULTS
Fifteen cases of patients with severe ongoing OOGIB sub-
mitted for CE were identified (4.5% of the examinations
carried out during the considered period) (11 men; mean age
69.9  20.1 years, range 29–94 years). All patients presented
with melena and/or hematochezia. In eight patients it was the
first episode of severe bleeding. The remaining seven had
suffered previous episodes, but the etiology of the bleeding
was unknown.Mean hemoglobin (Hb) level at the time of the
exam was 8.4  1.2 g/dL (range 5.9–10 g/dL) with a mean
transfusion requirement of 6.3  4.1 RBC units (range 2–16
units).
The mean time from admission until endoscopic examina-
tion by capsule was 4.1  4.4 days (range 0–15 days), but,
in four patients, CE was carried out in the first 12 h after
hospitalization. The demographic and clinical data of the
patients are presented in Table 1.
The capsule was easily swallowed by all patients, no tech-
nical problems or complications occurred during the exami-
nations and the capsule was naturally excreted in all patients.
Total enteroscopy was achieved in 11 patients (73.3%), with
four cases of partial enteroscopy resulting from slow small
bowel transit.
The patients were divided into four groups in accordance
with the findings (Table 2). Group A included seven patients
with active bleeding in the small bowel (Figs 1–3); group B
included four patients with signs of recent bleeding in the
small bowel and lesions with hemorrhagic potential (Fig. 4);
group C included two patients with cecal blood residues but
no potential bleeding lesions in the small bowel (Fig. 5) and
group D included two patients without blood or clots in the
GI tract but jejunal lesions.
Positive relevant findings concerning bleeding were
detected in 80% of patients.The etiology of the bleeding was
diagnosed in 11 patients (73.3%). In one additional patient,
active bleeding in the small bowel was seen, but no causative
lesion was identified.
We found P2 lesions in eight patients (53.3%), active
bleeding with P1 lesion in one (6.7%), active bleeding but no
lesion in another one (6.7%) and P1 lesions without active
bleeding in three (20%). Specific therapeutic measures were
proposed in 12 patients (80%) but carried out in 11 (73.3%)
because one refused surgery. Of the 11 patients, two were
managed surgically with resection of a small bowel tumor
(gastrointestinal stromal tumor [GIST]). Four were managed
endoscopically with DBE and fulguration of angiodysplasias
in two, DBE followed by intraoperative enteroscopy in one
and endoscopic resection of a large subepithelial ulcerated
lesion (lipoma) in the final patient. Five patients were
Table 1. Demographic data and clinical history of patients with




Mean age (years) 69.9 20.1 29–94
Males 65.6 21.5 29–94
Females 81.8 8.5 75–94
Mean Hb level at time of CE (g/dL) 8.4 1.2 5.9–10
Mean blood transfusions (units) 6.3 4.1 2–16
CE, capsule endoscopy; Hb, hemoglobin; OOGIB, obscure-overt
gastrointestinal bleeding.
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managed conservatively with the introduction of beta-
blockers in patients with portal hypertension enteropathy,
chemotherapy in a patient with disseminated B-cell lym-
phoma and suspension of NSAIDs in one patient with iatro-
genic small bowel lesions.
Rebleeding occurred in two patients, with one requiring
specific measures after CE.This patient, in group D, found to
have a jejunal ulcer not considered to be the cause of the
hemorrhage, was given a DBE.This procedure was inconclu-
sive and was followed by an intraoperative enteroscopy that
revealed the presence of duodenal varices (fourth portion).
This patient was the only one who had red blood cell scintig-
raphy and angiography, with both methods being unsuccess-
ful in showing the cause of the bleeding.
Both patients in group C were given a second colonoscopy
that did not fid any relevant lesion.
Table 2. CE findings, therapeutic procedures and final outcome of patients with severe OOGIB after standard endoscopic evalu-
ation
Group/Patients Findings Therapy Rebleeding
Group A Active small bowel bleeding
Male, 74 years Subepithelial ulcerated lesion Surgery: GIST No
Male, 68 years Irregular area of mucosa Surgery: GIST No
Female, 81 years Active bleeding; angiodysplasia Enteroscopy: argon-plasma No
Male, 92 years Active bleeding; angiodysplasia Enteroscopy: argon-plasma No
Male, 72 years Subepithelial ulcerated lesion Endoscopic excision: large ileocecal lipoma No
Female, 94 years Jejunal tumor Refused surgery: probable carcinoma Yes
Female, 77 years Active bleeding; no lesion identified No No
Group B Signs of recent bleeding
Male, 64 years Portal hypertension enteropathy Beta-blockers No
Male, 58 years Portal hypertension enteropathy Beta-blockers No
Male, 41 years Portal hypertension enteropathy Beta-blockers No
Male, 87 years Multiple small bowel ulcers Suspended NSAIDs No
Group C Clots in cecum; no small bowel lesion
Male, 94 years No relevant lesion No No
Female, 75 years No relevant lesion No No
Group D No blood in GI tract
Male, 29 years Jejunal ulcer DBE and intraoperative enteroscopy Yes
Male, 42 years Jejunal ulcer with visible vessel Chemotherapy: disseminated B-cell lymphoma No
CE, capsule endoscopy; DBE, double balloon enteroscopy; GIST, gastrointestinal stromal tumor; NSAIDs, non-steroidal anti-inflammatory drugs;
OOGIB, obscure-overt gastrointestinal bleeding.
Fig. 1. Subepithelial ulcerated lesion with active bleeding. Fig. 2. Irregular area of mucosa with blood and an adherent
clot.
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DISCUSSION
Using CE early in the course of OOGIB is attractive because
it has no major complications, it is easy to perform with
no discomfort to the patient, its diagnostic yield is larger in
these cases and will, at least, reveal the location of the
bleeding.1,5,16–18 In fact, in the present study, only two patients
had no blood residues in the digestive tract and seven
patients presented active bleeding at the time of the exam,
clearly revealing the source/location of the hemorrhage, with
no need for further diagnostic work-up. In the absence of
blood or lesions, there is no need to proceed with further
investigations unless rebleeding occurs, avoiding unnecessary
human and financial costs.4
In a prospective study, Apostolopoulos et al., had already
stated that CE appeared to have a high diagnostic yield in
patients with acute, mild-to-moderate, active bleeding but
patients with severe hemorrhage were excluded.18 Our
report, albeit retrospective and with a limited number of
patients, seems to demonstrate that CE can also be helpful in
patients with severe, ongoing OGIB. In fact, CE was helpful
in all cases but one, establishing the location or the etiology
of the lesions,most of them P2 type,with a positive impact on
the subsequent investigation or chosen therapy.
Angiography, a procedure that has an overall positivity
rate in acute lower GI bleeding of 27%–77% (mean 47%), is
another option in these patients.21 Therapeutic procedures
are possible with angiography, but the number of patients
successfully treated with this technique is small and the com-
plications are frequent and sometimes severe.22 In fact, CE
has a higher diagnostic yield than angiography in acute
OOGIB.23 In our series, angiography was used in the only
case in which CE failed to find the etiology of a recurrent
gastrointestinal hemorrhage. However, angiography also
failed in identifying the source of bleeding.
DBE is also an option in these patients. The diagnostic
and therapeutic capabilities of this technique allow it to be
a reasonable alternative to CE in patients with severe
ongoing OOGIB. In fact, the use of push enteroscopy, fol-
lowed, in the case of failure, by CE, was proposed by Dulai
and Jensen,4 although the opposite sequence has also been
suggested by Fleischer.24 The recommended approach in
suspected small-bowel bleeding is that DBE should be used
after initial diagnosis with CE.25 The same applies, in our
Fig. 3. Irregular, congestive, friable lesion suggestive of small
bowel carcinoma.
Fig. 4. Portal hypertension enteropathy.
Fig. 5. Blood residues in the cecum.
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opinion, to patients with severe ongoing OOGIB. In fact, in
these patients, after the initial standard endoscopic evalua-
tion, CE should be the procedure of choice, followed by
DBE in accordance with the findings. This approach would
avoid a long endoscopic procedure with DBE, probably not
diagnostic in many cases given the known difficulty in per-
forming total enteroscopy with this technique.26 Choosing
CE as the first diagnostic procedure is advantageous also
because it is helpful in determining the route of insertion of
the enteroscope.27
The drawbacks associated with the use of CE in patients
with OOGIB must also be considered. The first is the
absence of control of the image acquisition process that, in
the presence of debris, may jeopardize the observation.
However, a bowel-cleaning preparation probably allows a
better examination, but may interfere with interpretation, as
blood residues are eliminated in the process. In our series,
some CE examinations were carried out immediately after
colonoscopy and, apparently, the previous bowel prepara-
tion did not interfere with the interpretation of the images.
Another difficulty with CE is the assessment of the exact
location of findings. It can grossly be estimated by consider-
ing the time that elapsed after the first duodenal image, total
time of transit in the small bowel and macroscopic charac-
teristics of the surrounding mucosa.28 Another drawback
associated with the use of CE in these patients is that the
result of the enteroscopy is obtained hours after swallowing
the capsule. Rapid alternating between two different record-
ers, allowing an almost real-time reading, can solve this
problem.29 The ‘Rapid Access’ system may also allow a
similar approach.28 The possibility of an incomplete exami-
nation of the small bowel, missing lesions in the distal seg-
ments, must also be considered. The reported frequency of
this occurrence is variable, but may reach up to one-third of
the exams.4 In our series, this occurred in four patients
(26.7%).A second CE or retrograde DBE may be helpful if
the bleeding persists or recurs.30 Fortunately, in our four
patients, there was no need for further studies because the
lesions were well documented in the obtained video. Finally,
the absence of therapeutic capabilities is also a major limi-
tation of this technique.
There are other risks and difficulties associated with CE
that may be increased in patients actively bleeding, includ-
ing incapability to swallow the capsule, risk of vomiting/
aspiration, delayed gastric emptying time and masking the
sources of bleeding by blood and clots. Our patients had no
difficulties in swallowing the device.We used a prokinetic as
it can increase the likelihood of complete small bowel
examination with CE.31 In our series, in only one case of
active bleeding was no lesion identified. On the contrary,
our major diagnostic failure occurred in the setting of the
absence of blood. In fact, CE failed to identify duodenal
varices in one patient. Even DBE, with cautious observa-
tion of the duodenum, was insufficient to establish diagno-
sis, achieved only by transillumination during intraoperative
enteroscopy.
In conclusion, our results show that CE might be useful in
patients with severe OOGIB because, without discomfort to
the patient or major complications, this methodology pro-
vides positive findings in the majority of patients, avoiding
further diagnostic procedures and allowing specific therapeu-
tic measures.
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